Theratechnologies (THTX) Competitors $3.25 +0.01 (+0.31%) Closing price 04:00 PM EasternExtended Trading$3.24 0.00 (-0.15%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock THTX vs. TSHA, ORGO, TBPH, MAZE, MRVI, KROS, BCAX, RLAY, TYRA, and SAGEShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include Taysha Gene Therapies (TSHA), Organogenesis (ORGO), Theravance Biopharma (TBPH), Maze Therapeutics (MAZE), Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Its Competitors Taysha Gene Therapies Organogenesis Theravance Biopharma Maze Therapeutics Maravai LifeSciences Keros Therapeutics Bicara Therapeutics Relay Therapeutics Tyra Biosciences Sage Therapeutics Theratechnologies (NASDAQ:THTX) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends. Which has more volatility & risk, THTX or TSHA? Theratechnologies has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Does the media refer more to THTX or TSHA? In the previous week, Taysha Gene Therapies had 13 more articles in the media than Theratechnologies. MarketBeat recorded 14 mentions for Taysha Gene Therapies and 1 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 0.98 beat Taysha Gene Therapies' score of 0.28 indicating that Theratechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theratechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer THTX or TSHA? Taysha Gene Therapies has a consensus target price of $8.29, indicating a potential upside of 188.70%. Given Taysha Gene Therapies' higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Taysha Gene Therapies 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, THTX or TSHA? Theratechnologies has higher revenue and earnings than Taysha Gene Therapies. Theratechnologies is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$85.87M1.74-$8.31M-$0.19-17.11Taysha Gene Therapies$8.33M73.96-$89.30M-$0.34-8.44 Is THTX or TSHA more profitable? Theratechnologies has a net margin of -10.85% compared to Taysha Gene Therapies' net margin of -1,144.97%. Theratechnologies' return on equity of 0.00% beat Taysha Gene Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-10.85% N/A -9.83% Taysha Gene Therapies -1,144.97%-78.44%-44.82% Do insiders & institutionals have more ownership in THTX or TSHA? 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryTheratechnologies and Taysha Gene Therapies tied by winning 8 of the 16 factors compared between the two stocks. Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$149.44M$3.11B$5.73B$9.56BDividend YieldN/A2.23%4.53%4.08%P/E Ratio-17.1120.4330.4625.16Price / Sales1.74238.53392.5787.62Price / CashN/A42.3737.0358.50Price / Book-5.917.918.956.21Net Income-$8.31M-$54.72M$3.26B$265.38M7 Day Performance0.93%1.66%1.06%-1.13%1 Month Performance3.50%5.88%4.31%-0.71%1 Year Performance142.54%8.72%28.39%18.86% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$3.25+0.3%N/A+133.1%$149.44M$85.87M-17.11140News CoverageShort Interest ↓TSHATaysha Gene Therapies3.3874 of 5 stars$2.76+1.5%$8.17+195.9%+25.3%$583.88M$8.33M-8.12180Analyst RevisionORGOOrganogenesis4.2575 of 5 stars$4.61+1.3%$7.50+62.7%+70.3%$577.84M$482.04M-32.93950TBPHTheravance Biopharma2.1713 of 5 stars$11.40-1.0%$21.33+87.1%+62.9%$576.02M$64.38M-9.66110MAZEMaze TherapeuticsN/A$13.47+2.5%$25.60+90.1%N/A$575.49M$167.50M0.00121Positive NewsAnalyst RevisionMRVIMaravai LifeSciences3.8807 of 5 stars$2.06-6.4%$6.64+222.3%-72.6%$560.25M$259.18M-1.81610Options VolumeKROSKeros Therapeutics2.9936 of 5 stars$13.35-2.8%$30.00+124.7%-69.9%$557.65M$3.55M43.07100News CoverageBCAXBicara Therapeutics1.7162 of 5 stars$9.99-2.1%$31.86+218.9%N/A$556.27MN/A0.0032Analyst ForecastRLAYRelay Therapeutics2.0166 of 5 stars$3.25+0.9%$17.25+430.8%-53.1%$555.16M$10.01M-1.67330TYRATyra Biosciences2.3328 of 5 stars$10.10-3.3%$30.83+205.3%-53.4%$554.79MN/A-6.2020News CoverageEarnings ReportSAGESage Therapeutics3.4054 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690 Related Companies and Tools Related Companies TSHA Competitors ORGO Competitors TBPH Competitors MAZE Competitors MRVI Competitors KROS Competitors BCAX Competitors RLAY Competitors TYRA Competitors SAGE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THTX) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access